MCID: INS002
MIFTS: 56

in Situ Carcinoma

Categories: Cancer diseases, Oral diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 14
Carcinoma in Situ 41 69

Classifications:



Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to endometrium carcinoma in situ and breast carcinoma in situ. An important gene associated with in Situ Carcinoma is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Nolvadex and Valstar have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and cervix, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 72 Carcinoma in situ (CIS), also known as in situ neoplasm, is a group of abnormal cells. While they are a... more...

Related Diseases for in Situ Carcinoma

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm Lip Carcinoma in Situ
in Situ Carcinoma Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 endometrium carcinoma in situ 32.5 PGR TP53
2 breast carcinoma in situ 31.5 BRCA1 ERBB2 ESR1 PGR TP53
3 cervix uteri carcinoma in situ 30.8 CDKN2A KRT17 SERPIND1 TP53
4 mucinous adenocarcinoma 29.6 CDKN2A EGFR TP53
5 papillary carcinoma 29.6 CDH1 ERBB2 PGR
6 breast disease 29.4 ERBB2 ESR1 KRT5 PGR TP53
7 bile duct carcinoma 29.4 ANXA8L1 CDH1 TP53
8 pleomorphic adenoma 29.3 ERBB2 KRT14 TP53
9 adenocarcinoma 29.3 CDH1 CDKN2A EGFR ERBB2 TP53
10 squamous cell carcinoma 29.3 CDH1 CDKN2A EGFR ERBB2 TP53
11 nasopharyngeal carcinoma 28.9 CDH1 CDKN2A EGFR TP53
12 papilloma 28.9 CDKN2A KRT14 KRT5 TP53
13 breast cancer 27.4 BRCA1 CDH1 EGFR ERBB2 ESR1 KIAA0100
14 oral cavity carcinoma in situ 11.0
15 nasal cavity carcinoma in situ 11.0
16 prostate carcinoma in situ 11.0
17 skin carcinoma in situ 11.0
18 eye carcinoma in situ 11.0
19 trachea carcinoma in situ 11.0
20 colon carcinoma in situ 11.0
21 larynx carcinoma in situ 11.0
22 bladder carcinoma in situ 11.0
23 esophagus carcinoma in situ 11.0
24 liver carcinoma in situ 11.0
25 stomach carcinoma in situ 11.0
26 rectum carcinoma in situ 11.0
27 vulvar syringoma 10.6 ESR1 PGR
28 lung leiomyoma 10.6 ESR1 PGR
29 endometrial clear cell adenocarcinoma 10.6 ESR1 TP53
30 vulvar benign neoplasm 10.6 ESR1 PGR
31 trigonitis 10.6 ESR1 PGR
32 vulvar leiomyoma 10.6 ESR1 PGR
33 scirrhous adenocarcinoma 10.6 ERBB2 PGR
34 breast apocrine carcinoma 10.6 ERBB2 PGR
35 vestibular gland benign neoplasm 10.5 ESR1 PGR TP53
36 bartholin's gland adenoma 10.5 ESR1 PGR TP53
37 cervical carcinosarcoma 10.5 ESR1 PGR TP53
38 adenosarcoma 10.5 ESR1 PGR TP53
39 brain ependymoma 10.5 EGFR TP53
40 progesterone resistance 10.5 ESR1 FKBP4 PGR
41 glassy cell carcinoma of the cervix 10.5 ERBB2 ESR1 PGR
42 progesterone-receptor positive breast cancer 10.5 ERBB2 ESR1 PGR
43 breast intraductal proliferative lesion 10.5 EGFR ERBB2
44 brain stem astrocytic neoplasm 10.5 CDKN2A TP53
45 uterine body mixed cancer 10.4 ERBB2 PGR TP53
46 vulvar dystrophy 10.4 CDKN2A PGR
47 malignant spiradenoma 10.4 KRT5 TP53
48 nosophobia 10.4 BRCA1 PGR
49 gastric signet ring cell adenocarcinoma 10.4 CDH1 ESR1 PGR
50 prostatic hypertrophy 10.4 EGFR ESR1 PGR

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

MGI Mouse Phenotypes related to in Situ Carcinoma:

43 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 EGFR ESR1 ERBB2 FKBP4 KRT17 ITGB4
2 homeostasis/metabolism MP:0005376 10.41 ERBB2 EGFR ESR1 FKBP4 ITGB4 KRT14
3 cardiovascular system MP:0005385 10.4 ERBB2 EGFR ESR1 ITGB4 PPIA NR3C1
4 digestive/alimentary MP:0005381 10.38 EGFR ESR1 ERBB2 FKBP4 KRT17 ITGB4
5 growth/size/body region MP:0005378 10.38 ERBB2 EGFR ESR1 KRT14 FKBP4 KRT17
6 mortality/aging MP:0010768 10.36 ERBB2 EGFR ESR1 FKBP4 KRT17 ITGB4
7 hematopoietic system MP:0005397 10.34 EGFR ESR1 KRT14 PPIA NR3C1 PRDX2
8 immune system MP:0005387 10.34 EGFR ESR1 KRT14 ITGB4 PPIA NR3C1
9 endocrine/exocrine gland MP:0005379 10.33 ERBB2 EGFR ESR1 KRT14 FKBP4 PPIA
10 integument MP:0010771 10.32 EGFR ESR1 ERBB2 FKBP4 KRT17 ITGB4
11 embryo MP:0005380 10.21 CDKN2A ERBB2 EGFR ESR1 FKBP4 PGR
12 adipose tissue MP:0005375 10.14 EGFR ESR1 KRT14 NR3C1 TP53 BRCA1
13 craniofacial MP:0005382 10.12 ERBB2 EGFR KRT14 KRT17 ITGB4 KRT5
14 muscle MP:0005369 10.06 CDKN2A ERBB2 EGFR ESR1 NR3C1 SERPIND1
15 neoplasm MP:0002006 10.02 ERBB2 EGFR ESR1 KRT14 PGR TP53
16 limbs/digits/tail MP:0005371 10 ERBB2 EGFR ESR1 KRT5 PGR TP53
17 no phenotypic analysis MP:0003012 9.97 EGFR ESR1 KRT17 KRT5 NR3C1 PGR
18 renal/urinary system MP:0005367 9.81 EGFR ESR1 FKBP4 ITGB4 NR3C1 SERPIND1
19 pigmentation MP:0001186 9.73 CDKN2A EGFR KRT14 KRT17 TP53 BRCA1
20 reproductive system MP:0005389 9.7 ERBB2 EGFR ESR1 KRT14 FKBP4 NR3C1
21 respiratory system MP:0005388 9.28 CDKN2A ERBB2 EGFR ESR1 KRT14 ITGB4

Drugs & Therapeutics for in Situ Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Nolvadex 17 45 TAMOXIFEN CITRATE AstraZeneca October 1998
2
Valstar 17 VALRUBICIN Anthra Pharmaceuticals October 1998

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 359)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
2
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
3
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
4
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
5
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
6
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
7
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
8 Racepinephrine Approved Phase 4,Phase 3,Phase 2 329-65-7
9
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3 21645-51-2
10
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
11 interferons Phase 4,Phase 3,Phase 2,Phase 1
12 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
14 Mitomycins Phase 4,Phase 3,Phase 2
15 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
17 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
19 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
26 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Interferon-alpha Phase 4,Phase 3,Phase 1,Phase 2
29 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
31 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Respiratory System Agents Phase 4,Phase 2
35 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
36 Adrenergic Agents Phase 4,Phase 2
37 Adrenergic Agonists Phase 4,Phase 2
38 Chelating Agents Phase 4,Phase 3,Phase 2
39 Adrenergic alpha-Agonists Phase 4,Phase 2
40 Mydriatics Phase 4,Phase 2
41 Adrenergic beta-Agonists Phase 4,Phase 2
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
43 Vasoconstrictor Agents Phase 4,Phase 2
44 Anesthetics, Local Phase 4,Phase 3,Phase 2
45 Anti-Asthmatic Agents Phase 4,Phase 2
46 Anticoagulants Phase 4,Phase 3,Phase 2
47 Epinephryl borate Phase 4,Phase 3,Phase 2
48 Autonomic Agents Phase 4,Phase 3,Phase 2
49 Bronchodilator Agents Phase 4,Phase 2
50 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 632)

# Name Status NCT ID Phase Drugs
1 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
2 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
3 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
4 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
5 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
6 Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
7 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
8 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
9 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
10 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Recruiting NCT02087384 Phase 4 Placebo
11 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Recruiting NCT03051516 Phase 4
12 Difference of Gastric Microbiota in the Process of Correa's Model. Recruiting NCT02833363 Phase 4
13 FASTER-Tlalpan Study Active, not recruiting NCT03105856 Phase 4
14 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4 Tachosil
15 Effectiveness of Cervical Screening in HPV Vaccinated Women Enrolling by invitation NCT02149030 Phase 4
16 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Not yet recruiting NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
17 Endoscopy Screening for Esophageal Cancer Terminated NCT00927446 Phase 4
18 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
19 Topical 5-ALA Photodynamic Therapy for the Treatment of Verruca Vulgaris Unknown status NCT00155584 Phase 3
20 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
21 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
22 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
23 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3
24 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
25 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
26 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
27 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
28 Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
29 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
30 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
31 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
32 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
33 Biological Therapy in Treating Patients With Bladder Cancer Completed NCT00003779 Phase 3
34 Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
35 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
36 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
37 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
38 Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer Completed NCT01442519 Phase 3 electromotive mitomycin
39 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
40 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting Completed NCT02560584 Phase 3 Hexaminolevulinate hydrochloride
41 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
42 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
43 Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Completed NCT00995020 Phase 3
44 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3
45 Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit Completed NCT00237562 Phase 3
46 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
47 A Trial of Two Electrosurgical Conizations: Histopathological Analysis of Excision Margins Completed NCT01929993 Phase 3
48 ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
49 Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
50 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

38
Breast, Testes, Cervix, Prostate, Skin, Lung, Lymph Node

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 144)
# Title Authors Year
1
Contamination artifact that mimics in-situ carcinoma on contrast-enhanced digital mammography. ( 28987661 )
2017
2
In situ carcinoma in a hybrid cyst: a case report. ( 27792259 )
2017
3
Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. ( 28094198 )
2017
4
Hospitalizations associated with malignant neoplasia and in situ carcinoma in the anus and penis in men and women during a 5-year period (2009-2013) in Spain: An epidemiological study. ( 28708948 )
2017
5
The detection of Felis catus papillomavirus 3 DNA in a feline bowenoid in situ carcinoma with novel histologic features and benign clinical behavior. ( 27423734 )
2016
6
Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma. ( 26589439 )
2016
7
Solid papillary carcinoma of the nipple: an in situ carcinoma or an expansive growth tumor? ( 28195265 )
2016
8
Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels. ( 27488105 )
2016
9
Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma. ( 27048100 )
2016
10
A New Hitherto Unreported Histopathologic Manifestation of Mammary Analogue Secretory Carcinoma: "Masked MASC" Associated With Low-grade Mucinous Adenocarcinoma and Low-grade In Situ Carcinoma Components. ( 26808131 )
2016
11
Reply to staging classification for cancer of the ovary and fallopian tube should include in situ carcinoma. ( 26535793 )
2015
12
In situ carcinoma developed over oral lichen planus: a case report with analysis of BUB3, p16, p53, Ki67 and SOX4 expression. ( 26398519 )
2015
13
Staging classification for cancer of the ovary and fallopian tube should include in situ carcinoma. ( 26535923 )
2015
14
Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma. ( 26404127 )
2015
15
5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. ( 26494415 )
2015
16
Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up. ( 24121179 )
2014
17
Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas. ( 23722505 )
2013
18
In situ carcinoma of the conjunctiva: surgical excision associated with cryotherapy. ( 24092968 )
2013
19
Genomic characterization of Felis catus papillomavirus-3: a novel papillomavirus detected in a feline Bowenoid in situ carcinoma. ( 23639476 )
2013
20
Loss of retinoblastoma protein, but not p53, is associated with the presence of papillomaviral DNA in feline viral plaques, Bowenoid in situ carcinomas, and squamous cell carcinomas. ( 21930804 )
2012
21
Hemosuccus pancreaticus caused by in situ carcinoma of the pancreas. ( 23012009 )
2012
22
p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. ( 21804388 )
2011
23
Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. ( 19875955 )
2010
24
Head and neck in situ carcinoma: survival analysis of the Thuringian cancer registration database. ( 20227329 )
2010
25
Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. ( 19521656 )
2010
26
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. ( 19584157 )
2009
27
In situ carcinoma of pancreas diagnosed by EUS-FNA. ( 18278717 )
2008
28
Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast. ( 18983606 )
2008
29
Intracapsular (in situ) carcinoma ex pleomorphic adenoma with unusual clinical and histological features. ( 18288478 )
2008
30
D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. ( 18206495 )
2008
31
Detection of papillomaviral sequences in feline Bowenoid in situ carcinoma using consensus primers. ( 17610489 )
2007
32
In situ carcinoma - can we predict which patient will come back with a recurrence? ( 17996643 )
2007
33
Very early cytological and DNA-cytometric diagnosis of in situ carcinoma in an immunosuppressed liver transplant recipient. ( 16393256 )
2006
34
Very early cytological and DNA-cytometric diagnosis of in situ carcinoma in an immunosuppressed liver transplant recipient. ( 16918607 )
2006
35
Invasive squamous cell carcinoma arising from verrucous carcinoma. Recognition of verrucous carcinoma of skin as an in situ carcinoma. ( 16935807 )
2006
36
An in situ carcinoma of the pancreas forming 2 invasive ductal carcinomas. ( 16025010 )
2005
37
Survival of in situ carcinoma of cervix uteri: a 50-year follow-up in Finland. ( 15386351 )
2004
38
Human papillomavirus and extragenital in situ carcinoma. ( 15237266 )
2004
39
Expression of mismatch repair proteins in invasive and in situ carcinoma of the breast. ( 15523909 )
2004
40
Heterogeneous versus homogeneous genetic nature of multiple foci of in situ carcinoma of the breast. ( 14652818 )
2003
41
Severe high-grade dysplasia and in-situ carcinoma of the common bile duct and pancreatic duct. ( 12788411 )
2003
42
Collagenous spherulosis of the breast in association with in situ carcinoma. ( 12540997 )
2002
43
Incidence of second cancers among women with in situ carcinoma of the breast. ( 14965621 )
2001
44
MnSOD expression is less frequent in tumour cells of invasive breast carcinomas than in in situ carcinomas or non-neoplastic breast epithelial cells. ( 11592093 )
2001
45
Fine-needle aspiration cytology of the breast: Invasive vs. in situ carcinoma. ( 11466818 )
2001
46
Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. ( 11176073 )
2001
47
8. The dilemma of in situ carcinoma of the breast. ( 11777293 )
2001
48
Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. ( 11685554 )
2001
49
Loss of heterozygosity among tumor suppressor genes in invasive and in situ carcinoma of the uterine cervix. ( 11240714 )
2000
50
Recent trends of in situ carcinoma of the breast and mammographic screening in the Florence area, Italy. ( 10482490 )
1999

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 BRCA1 CDH1 CDKN2A EGFR ERBB2 TP53
2 12.59 AGTR1 CDH1 CDKN2A EGFR ERBB2 ESR1
3
Show member pathways
12.4 CDKN2A EGFR ERBB2 ESR1 FKBP4 TP53
4
Show member pathways
12.39 CDH1 EGFR ERBB2 TP53
5 12.37 BRCA1 CDKN2A EGFR ERBB2 TP53
6
Show member pathways
12.22 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
7 12.17 EGFR ERBB2 ESR1 TP53
8
Show member pathways
12.08 BRCA1 CDKN2A ESR1 NR3C1 PGR
9
Show member pathways
12 CDKN2A EGFR ERBB2 TP53
10 11.95 BRCA1 CDH1 EGFR ESR1 TP53
11
Show member pathways
11.81 EGFR ERBB2 ESR1 PGR
12 11.75 BRCA1 EGFR FKBP4
13
Show member pathways
11.74 ESR1 NR3C1 PGR
14 11.62 CDH1 EGFR ERBB2
15 11.62 BRCA1 CDKN2A ERBB2 TP53
16 11.56 BRCA1 ERBB2 TP53
17 11.54 EGFR ERBB2 TP53
18 11.5 BRCA1 ERBB2 ITGB4
19 11.42 CDH1 CDKN2A EGFR ERBB2 TP53
20 11.41 CDKN2A EGFR TP53
21 11.05 CDH1 EGFR ERBB2 ITGB4
22 11.01 FKBP4 KRT14 KRT17 KRT5 NR3C1 TP53
23 10.59 FKBP4 NR3C1

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 ANXA8L1 CDH1 FKBP4 ITGB4 KRT14 KRT17
2 cytoplasm GO:0005737 9.5 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
3 protein complex GO:0043234 9.43 BRCA1 EGFR ESR1 FKBP4 NR3C1 TP53

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 BRCA1 CDKN2A EGFR ESR1 NR3C1 PGR
2 positive regulation of transcription, DNA-templated GO:0045893 9.63 BRCA1 CDH1 CDKN2A EGFR ESR1 TP53
3 positive regulation of cell growth GO:0030307 9.61 EGFR ERBB2 KRT17
4 steroid hormone mediated signaling pathway GO:0043401 9.58 ESR1 NR3C1 PGR
5 replicative senescence GO:0090399 9.46 CDKN2A TP53
6 negative regulation of immature T cell proliferation in thymus GO:0033088 9.32 CDKN2A ERBB2
7 cellular response to indole-3-methanol GO:0071681 9.26 BRCA1 CDH1
8 epidermis development GO:0008544 9.26 EGFR KRT14 KRT17 KRT5
9 hemidesmosome assembly GO:0031581 8.8 ITGB4 KRT14 KRT5

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 CDKN2A EGFR ESR1 NR3C1 TP53
2 protein phosphatase binding GO:0019903 9.58 EGFR ERBB2 TP53
3 steroid hormone receptor activity GO:0003707 9.43 ESR1 NR3C1 PGR
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.37 EGFR ERBB2
5 enzyme binding GO:0019899 9.35 BRCA1 EGFR ESR1 PGR TP53
6 nitric-oxide synthase regulator activity GO:0030235 9.16 EGFR ESR1
7 steroid binding GO:0005496 8.8 ESR1 NR3C1 PGR
8 protein binding GO:0005515 10.36 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....